Exact Sciences (EXAS) Jefferies Global Healthcare Conference summary

Industry trends and competitive landscape

• Cancer diagnostics is entering a golden era with rapid innovation and improved patient outcomes, especially in screening and therapy selection.

• Blood-based colorectal cancer screening tests are emerging, but current data shows they are less effective and more costly than established methods like colonoscopy and Cologuard.

• Recent modeling and guideline publications do not recommend blood-based tests as replacements for current screening methods.

• Market confusion and volatility are driven by new entrants and evolving data, but established screening methods remain preferred.

• Geneoscopy's stool RNA test faces challenges with Medicare coverage and must conduct further studies to meet regulatory requirements.

Product pipeline and data outlook

• A 20,000-patient study for a blood-based test is underway, with data expected in October; results will be released immediately upon completion.

• If blood-based tests meet Medicare's threshold (74% cancer detection, 10% false positive), approval could follow within six months, with a potential launch by late next year.

• Cologuard Plus, the next generation test, offers improved sensitivity, specificity, and cost-effectiveness, with FDA approval and launch targeted for next year.

• Cologuard Plus will have a modest price increase, the first in a decade, with strong physician interest in adoption.

• Ten internal product launches are planned over the next five years, leveraging the company's commercial platform.

Sales, marketing, and financial strategy

• Revenue has grown by $800 million over two years while reducing sales and marketing spend by over $100 million.

• Modest increases in sales force size are aimed at driving further growth, not just maintaining the base.

• The company expects 15% annual growth through 2027, with double-digit growth continuing beyond, and over 20% Adjusted EBITDA margins by 2027.

• A large, established sales force and payer relationships position the company to shape the market and respond to new entrants.

• Investments in sales and marketing are expected to yield significant operating margin leverage and support upcoming product launches.